Healthcare Industry News:  XIENCE 

Devices Regulatory Interventional Cardiology

 News Release - February 4, 2008

Tryton Medical Receives CE Mark Approval for its Side-Branch Stent

Tryton's revolutionary Side Branch Stent obtains CE Mark approval based on unprecedented results in the Tryton 1 (First-in-Man Study) with No Side-Branch Restenosis in 30 patients.

NEWTON, Mass., Feb. 4 (HSMN NewsFeed) -- Tryton Medical, Inc., the leading developer of stents designed for the definitive treatment bifurcation lesions announced that the company has received CE Mark approval for its Side Branch Stent. The Tryton Side-Branch Stent is a high performance cobalt chromium balloon-expandable coronary stent specifically developed for the complete treatment of the entire spectrum of coronary artery bifurcation disease. Approximately 540,000 annual procedures are performed to address bifurcation lesions, accounting for 20% of all coronary lesions treated. With the exception of Tryton's stent, no dedicated solution exists today that fully addresses these lesions.

The results of the Tryton 1 (First-In-Man) Study were presented by Prof. Patrick Serruys (Erasmus University/Thoraxcenter, Rotterdam NL) and Ralf Müller, M.D. (Helios Heart Centrum, Siegburg DE). When the Tryton cobalt chromium Bare Metal Stent was used with a standard drug eluting stent (Cypher Select, Taxus or XIENCE V), no side branch restenosis was observed in the 30 patients treated. The initial core laboratory quantitative analysis reported a late loss of 0.27 +/- 0.42 mm in the side branch and 0.12 +/- 0.47 mm in the main vessel. "This technology has the capacity to redefine the treatment of bifurcation lesions and resolve a frequent dilemma of the interventional cardiologist," said Professor Patrick W. J. C. Serruys, M.D., Head of the Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands.

"CE Mark will allow us to bring this important technology to market in Europe. A market launch is planned for May in conjunction with EuroPCR 2008," stated H. Richard Davis, CTO, Tryton Medical, Inc.

Every year, over half a million bifurcation coronary lesions are sub-optimally treated as no commercially available optimized solution exists for treating bifurcation lesions. As a result, cardiologists are forced to use a provisional strategy which avoids the deployment of a second stent -- leaving the side branch vulnerable to thrombosis and restenosis.

About Tryton Medical, Inc.

Tryton Medical, Inc. is the leading developer of stents that are designed to definitively treat bifurcation lesions. 540,000 bifurcation coronary lesions are sub-optimally treated every year with a variety of time consuming and technically challenging procedures. No optimized solution is commercially available for treating bifurcation lesions. As a result, cardiologists are forced to use a provisional strategy which avoids the deployment of a second stent -- leaving the un-stented side branch vulnerable to thrombosis and restenosis. The ability to definitively treat bifurcation lesions will enable PCI-stenting to become the new standard of care for the treatment of left main coronary artery disease rather than bypass surgery. Tryton Medical's Side- Branch Stent(TM) has all the characteristics of a state-of the art workhorse stent, providing proven stent coverage to bifurcation lesions while eliminating the need for provisional stenting. For more information on Tryton Medical, Inc., contact H. Richard Davis at +1-617-332-6060, hrdavis@trytonmedical.com or visit www.TrytonMedical.com


Source: Tryton Medical

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.